电子邮件 | dgi***@***.com | 获取Email |
---|
电子邮件 | dgi***@***.com | 获取Email |
---|
Crescendo Biologics is a private, clinical stage immuno-oncology company developing novel, targeted T cell enhancing Humabody® therapeutics. Leading its proprietary pipeline, Crescendo Biologics has developed CB307, a novel half-life extended CD137 x PSMA Humabody for the selective activation of tumour-specific T cells exclusively within the tumour microenvironment. CB307 is designed to achieve a longer lasting anti-cancer effect whilst avoiding systemic toxicity, and the clinical programme for CB307 is underway in patients with PSMA positive solid tumours (NCT04839991). CB693 is a half-life extended CD137 x MSLN Humabody and is the second proprietary clinical candidate from Crescendo's T cell enhancing pipeline. Crescendo is also developing CB213, a preclinical PD-1 x LAG-3 multi-specific Humabody. The Company's ability to develop multi-functional Humabody therapeutics is based on its unique, patent protected, transgenic mouse platform generating fully human VH domain building blocks (Humabody VH). These robust molecules can be configured to engage therapeutic targets in such a way that they deliver novel pharmacology and superior bio-distribution. This can lead to larger therapeutic windows compared to conventional IgG approaches. Humabody-based formats can also be applied across a range of non-cancer indications. Beyond Crescendo's proprietary pipeline, the Company has global, multi-target discovery and development collaborations with both Takeda and BioNTech and an exclusive, worldwide licensing agreement with Zai Lab for ZL-1102 (formerly CB001, an anti-IL-17A targeting Humabody), which is expected to enter global Phase 2 clinical development in patients with psoriasis. Crescendo Biologics is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Andera Partners, IP Group, BioNTech, Takeda and Quan Capital. For more information, please visit www.crescendobiologics.com.
公司 | Crescendo Biologics Limited |
---|---|
职位 | Senior Scientist I |
地点 | United Kingdom |
http://www.linkedin.com/in/davide-di-girolamo-ba467196 | |
部门 | master_engineering_technical |
头衔 | Senior Scientist at Crescendo Biologics |
Crescendo Biologics Limited Senior Scientist I
2022-09-01 -
AstraZeneca Scientist
2021-05-01 - 2022-09-01
AstraZeneca R&D Associate II
2018-09-01 - 2021-05-01
Envigo ++++ Assistant Study Analyst
2017-10-01 - 2018-08-01
Aquavit London Waiter
2017-03-01 - 2017-07-01
Davide Girolamo 在 Crescendo Biologics Limited 担任 Senior Scientist at Crescendo Biologics
Davide Girolamo 在 Crescendo Biologics Limited 的职位是 Senior Scientist at Crescendo Biologics
Davide Girolamo 的电子邮件地址是 dgi***@***.com
Davide Girolamo 的电话号码是 -
Davide Girolamo 的公司电话号码是 +441****
Davide Girolamo 在 research 工作。
Davide Girolamo 的一些同事包括Amelia Copas、Chris Wyre、Isabella Ascanio、Colette JohnstonDavide Girolamo、。
Davide Girolamo联系方式: 电子邮件地址:dgi***@***.com 电话号码:-
Davide Girolamo 的个人领英是:http://www.linkedin.com/in/davide-di-girolamo-ba467196
Davide Girolamo 的办公地点:meditrina babraham research campus #260, babraham, cambridgeshire, united kingdom
Top-ranked on G2 Crowd
全球B2B企业库 海关贸易数据 展会采购数据
全球B2B企业库
海关贸易数据
展销采购数据
Top-ranked on G2 Crowd